★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets More FDA Approvals Arise in Gene Editing Space, Renewed VC Rounds Begin to Ramp Up Shares of biotech firms focused on gene editing have been heating up this month, largely on the back of the…McAlinden Research PartnersMay 25, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Johnson & Johnson Faces Patent Hurdles in Drug Business, Potentially Setting the Tone for Pharma Peers Johnson & Johnson's most recent earnings data showed revenues and earnings per share growing more robustly than analysts anticipated. However,…McAlinden Research PartnersApril 18, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareFinanceⓁ PharmaceuticalsMarkets Pfizer’s M&A Strategy Sketches Roadmap for Pharma to Rebuild Pipelines, Overcome Patent Cliffs Pfizer's acquisition of Seagen, which is the largest biopharma deal since 2019, comes as products received in previous deals begin…McAlinden Research PartnersMarch 14, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Potential Pfizer-Seagen Tie Up Could Mark Largest Deal in Years, Continue to Propel Biopharma M&A Trend A potential acquisition of Seagen by Pfizer, likely in the neighborhood of $40.0 billion, would be the biggest biopharma deal…McAlinden Research PartnersFebruary 27, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcarePolitics & Policy Psychedelics Continue to Secure Legislative Backing Across the North American Continent Throughout the past month, legislators in nearly half a dozen US states have introduced bills focused on reforming laws that…McAlinden Research PartnersJanuary 30, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsTechnology AI Applications on the Rise in Healthcare, Boosting Biopharma and Diagnostics Efficiency Expectations for AI in healthcare, particularly biopharma and diagnostics, have been high for several years now. New partnerships and acquisitions may…McAlinden Research PartnersJanuary 17, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Price Hikes and Dealmaking Potential Are Key Pharma Catalysts for 2023 The biopharma industry is kicking off the year with price hikes and some early signs of a sustained uptick in…McAlinden Research PartnersJanuary 5, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene Editing FDA Approvals for Genetic Medicines Speed Ahead Despite Recent Setbacks in Base Editing Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…McAlinden Research PartnersDecember 8, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Another Blockbuster Biopharma Acquisition on Deck, May Set the Stage for Breakout M&A Activity in 2023 Three pharma giants are in the running to purchase Horizon Therapeutics in what will likely be a larger deal than…McAlinden Research PartnersDecember 1, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingⓁ PharmaceuticalsMarkets Pharma Fires Up More M&A Deals in Genetic Medicine as First CRISPR Drug Moves Closer to Commercialization Mergers and Acquisitions in the biopharma space continue to heat up, fueling a significant increase in large deals through the first 9…McAlinden Research PartnersOctober 19, 2022